Dachaigh › Lymphoma › Massachusetts › Boston
Sgrùdaidhean clionaigeach Lymphoma ann an Boston, MA
Tha 33 sgrùdaidhean airson Lymphoma a’ lorg phàirtichean aig làraichean ann agus timcheall air Boston (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
A’ fastadhÌre 2
- Dana-Farber Cancer Institute, Boston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
A’ fastadhÌre 1
- Beth Israel Deaconess Medical Center - Research, Boston
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
A’ fastadh
- Mass General Brigham, Boston
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
A’ fastadh
- Mass General Hospital, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
A’ fastadhÌre 1/2
- Dana Farber Cancer Institute., Boston
Epco, Zanu, Ritux for R/R FL or MZL
A’ fastadhÌre 2
- Dana-Farber Cancer Institute, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
A’ fastadhÌre 1/2
- Research Site, Boston
- Research Site, Boston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
A’ fastadhÌre 1/2
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
A’ fastadhÌre 3
- Research Site, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
A’ fastadhÌre 1/2
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
A’ fastadhÌre 1/2
- Massachusetts General Hospital, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
A’ fastadhÌre 4
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
The CARDIOPROTECT Trial
A’ fastadhÌre 2
- Beth Israel Deaconess Medical Center, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
A’ fastadhÌre 2
- Dana Farber Cancer Institute, Boston
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
A’ fastadhÌre 1/2
- Call for Information (Investigational Site 0026), Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
A’ fastadhÌre 1/2
- Dren Investigational Site, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
A’ fastadhSgrùdadh amharc
- Dana-Farber Cancer Institute, Boston
Remote Monitoring and Symptom Management Digital Application
A’ fastadh
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
A’ fastadh
- Massachusetts General Hospital Cancer Center, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
A’ fastadhÌre 1/2
- Dana Farber Cancer Institute, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
A’ fastadh
- Dana Farber Cancer Institute, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
A’ fastadhÌre 2
- Dana-Farber Cancer Institute, Boston
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
A’ fastadhÌre 2
- Beth Israel Deaconess Medical Center, Boston
Odronextamab in Low Tumor Volume Advanced FL
A’ fastadhÌre 2
- Beth Israel Deaconess Medical Center, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
A’ fastadhÌre 2
- Beth Israel Deaconess Medical Center, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
A’ fastadhÌre 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
A’ fastadhÌre 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
A’ fastadhÌre 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
A’ fastadh
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Avo In R/R And Previously Untreated MCL
A’ fastadhÌre 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
A’ fastadhÌre 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
A’ fastadhÌre 2
- Dana Farber Cancer Institute, Boston
HEME Home Transfusion Program
A’ fastadh
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Sgrùdaidhean Lymphoma ann am bailtean eile
- Houston, TX34 sgrùdaidhean
- New York City, NY33 sgrùdaidhean
- Washington, DC23 sgrùdaidhean
- Baldwin Park, CA21 sgrùdaidhean
- Chicago, IL20 sgrùdaidhean
- Durham, NC17 sgrùdaidhean
- St. Louis, MO15 sgrùdaidhean
- Philadelphia, PA15 sgrùdaidhean
- Cleveland, OH14 sgrùdaidhean
- Edison, NJ12 sgrùdaidhean
- Atlanta, GA12 sgrùdaidhean
- Seattle, WA12 sgrùdaidhean
Sgrùdaidhean eile ann an Boston
- Aillse a' bhroilleach112 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag90 sgrùdaidhean
- Aillse (gach seòrsa)85 sgrùdaidhean
- Ailse metastatach63 sgrùdaidhean
- Aillse colorectal63 sgrùdaidhean
- Ailseachadh nan Sgamhan62 sgrùdaidhean
- Cancer Ovarian61 sgrùdaidhean
- Aillse Prostata59 sgrùdaidhean
- Depression52 sgrùdaidhean
- Ailse Endometrial50 sgrùdaidhean
- Fàilligeadh a' Chridhe44 sgrùdaidhean
- Leukemia myeloid geur44 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.